AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SAVA
  4. [Form 4] Cassava Sciences, Inc. Insider Trading Activity

[Form 4] Cassava Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock SAVA logo
Cassava Sciences

NASDAQ:SAVA

SAVA Rankings

#6217 Ranked by Market Cap
N/A Ranked by Dividends
#192 Top Gainer

SAVA Latest News

Aug 4, 2025
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
Jun 30, 2025
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
May 8, 2025
Cassava Reports Q1 2025 Financials Results, Provides Business Update
May 1, 2025
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Apr 21, 2025
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

SAVA Latest SEC Filings

Aug 4, 2025
[8-K] Cassava Sciences, Inc. Reports Material Event
Jul 29, 2025
[SCHEDULE 13G/A] Cassava Sciences, Inc. SEC Filing
Jun 30, 2025
[8-K] Cassava Sciences, Inc. Reports Material Event

SAVA Stock Data

104.35M
42.13M
12.79%
32.45%
13%
Biotechnology
Pharmaceutical Preparations
United States
AUSTIN